A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Main Inclusion Criteria:

• Histologically-confirmed or cytologically confirmed diagnosis of advanced (StageIIIb/IIIc) or metastatic (Stage IV) (AJCC Edition 8) non-squamous NSCLC not amenableto curative therapy, irrespective of PD-L1 status and without actionable mutations (Phase 1b) targetable with first-line treatment.

• Histologically-confirmed or cytologically confirmed diagnosis of stage of advanced (Stage IIIb/IIIC) or metastatic (Stage IV) (AJCC, Edition 8) non-squamous NSCLC withSTK11 mutation, not amenable to curative therapy, irrespective of PD-L1 status andwithout actionable mutations (phase 2a) targetable with first-line treatment.

• Have not received prior systemic treatment for their advanced/metastatic NSCLC

• Have measurable disease per RECIST 1.1 as assessed by the investigator

Main Exclusion Criteria:

• Has received any prior chemotherapy or biological therapy for locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) adenocarcinoma of the lung

• Received radiation therapy within 2 weeks prior to starting study treatment or hasnot recovered (i.e. <=Grade 1 at baseline) from AEs due to a previous radiationtherapy

• Major surgery within 28 days prior to start of study treatment and failure to haverecovered adequately from the complications of the surgery/intervention prior to thefirst dose of study treatment